Aura Biosciences, Inc. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Aura Biosciences, Inc. (AURA) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$463.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-11
- Aura Biosciences, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$463.00K.
- Aura Biosciences, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$105.00K.
- Aura Biosciences, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was -$171.00K.
- Aura Biosciences, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was $44.00K, a 94.43% decline year-over-year.
- Aura Biosciences, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was -$365.00K.
- Aura Biosciences, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was -$276.00K, a 145.17% decline from fiscal 2023.
- Aura Biosciences, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $611.00K.
- Aura Biosciences, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was -$72.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$463.00K 10-Q · filed 2026-08-11 | -$568.00K 10-Q · filed 2026-08-11 | -$739.00K derived: sum of 3 quarters · filed 2026-08-11 | -$695.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$105.00K 10-Q · filed 2026-05-11 | -$276.00K derived: sum of 2 quarters · filed 2026-05-11 | -$232.00K derived: sum of 3 quarters · filed 2026-05-11 | -$312.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$171.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$127.00K derived: sum of 2 quarters · filed 2026-03-30 | -$207.00K derived: sum of 3 quarters · filed 2026-08-11 | -$365.00K 10-K · filed 2026-03-30 |
| 2025-09-30 | $44.00K 10-Q · filed 2025-11-13 | -$36.00K derived: sum of 2 quarters · filed 2026-08-11 | -$194.00K 10-Q · filed 2025-11-13 | -$538.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$80.00K 10-Q · filed 2026-08-11 | -$238.00K 10-Q · filed 2026-08-11 | -$582.00K derived: sum of 3 quarters · filed 2026-08-11 | $208.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$158.00K 10-Q · filed 2026-05-11 | -$502.00K derived: sum of 2 quarters · filed 2026-05-11 | $288.00K derived: sum of 3 quarters · filed 2026-05-11 | $87.00K derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$344.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $446.00K derived: sum of 2 quarters · filed 2026-03-30 | $245.00K derived: sum of 3 quarters · filed 2026-03-30 | -$276.00K 10-K · filed 2026-03-30 |
| 2024-09-30 | $790.00K 10-Q · filed 2025-11-13 | $589.00K derived: sum of 2 quarters · filed 2025-11-13 | $68.00K 10-Q · filed 2025-11-13 | $741.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$201.00K 10-Q · filed 2025-08-13 | -$722.00K 10-Q · filed 2025-08-13 | -$49.00K derived: sum of 3 quarters · filed 2025-08-13 | $40.00K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$521.00K 10-Q · filed 2025-05-15 | $152.00K derived: sum of 2 quarters · filed 2025-05-15 | $241.00K derived: sum of 3 quarters · filed 2025-05-15 | $63.00K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $673.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $762.00K derived: sum of 2 quarters · filed 2025-03-24 | $584.00K derived: sum of 3 quarters · filed 2025-03-24 | $611.00K 10-K · filed 2025-03-24 |
| 2023-09-30 | $89.00K 10-Q · filed 2024-11-12 | -$89.00K derived: sum of 2 quarters · filed 2024-11-12 | -$62.00K 10-Q · filed 2024-11-12 | $13.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$178.00K 10-Q · filed 2024-08-08 | -$151.00K 10-Q · filed 2024-08-08 | -$76.00K derived: sum of 3 quarters · filed 2024-08-08 | -$95.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $27.00K 10-Q · filed 2024-05-09 | $102.00K derived: sum of 2 quarters · filed 2024-05-09 | $83.00K derived: sum of 3 quarters · filed 2024-05-09 | -$40.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $75.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $56.00K derived: sum of 2 quarters · filed 2024-03-27 | -$67.00K derived: sum of 3 quarters · filed 2024-03-27 | -$72.00K 10-K · filed 2024-03-27 |
| 2022-09-30 | -$19.00K 10-Q · filed 2023-11-09 | -$142.00K derived: sum of 2 quarters · filed 2023-11-09 | -$147.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | -$123.00K 10-Q · filed 2023-08-09 | -$128.00K 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | -$5.00K 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |